Hi! Sign in or Registration
Looking for Investors
Israeli Companies Map
Made in Israel Online Exhibition
Wanted: Arts majors for high-tech
Author  Dafna Barmeli-Golan

Wanted: Arts majors for high-tech

From Globs

Technology companies are looking for creativity, flexibility, and the ability to think outside the box.

The average profile for a high-tech worker generally includes an education in systems engineering, computer engineering, or programming. However, in recent years, along with the blossoming of start-ups, many companies are turning to completely different fields to recruit workers. They are looking for creativity, flexibility, and the ability to think outside the box - attributes that are not necessarily typical of math and engineering graduates.

This trend, which characterizes high-tech and start-up companies, reflects a broader trend: companies are increasingly seeking to hire workers who are not conventional fits for the traditional requirements, so they can contribute to intellectual diversity, and help them to see things a little differently.

Shai Ozon, CEO of One1 Group, which employs 3,000 workers in IT, is a strong advocate of hiring management talents from different fields. “The idea is to bolster the management layer with people who come from different disciplines, and to diversify the style of management,” he says. “The reason is that we are in an industry that is constantly changing: the technology changes, the customers come from a wide variety for fields, and we are looking for people who will be able to speak in diverse languages, and not necessarily understand the intricate details of the product we are selling, but more relationship management and sales processes. We can teach them about the product.”

Are there problems with today’s training?

“Apple’s success did not stem from the fact that their computers were better than IBMs, rather from the synthesis of disciplines. For example, once, the role of information systems was to make sure the computer would work. Today, it is to give the business a competitive edge. It is not enough to speak the old language of technology; you need a broader business vision.”

What characteristics are you looking for in employees?

The people I am looking for may have backgrounds in law, industry and management, and as far as I'm concerned even art. The important thing is that they have some life experience. They first undergo an internship, for about a year and a half, in three levels of specialization: professional training in IT, management coaching, and in organizational culture the company’s business language. Each one of them will hold a variety of positions within the company along the way: projects, sales, etc., and they will see the big picture.

“I am looking for assertive, creative people, who understand business, and from that, also sales processes. Personality and ability to communicate are extremely valuable. It is hard to find managers, and, generally, people look in the wrong place. The match has to be as close as possible. We have built a rigorous program, and I want to have 10 employees enter the first round. If I end up with a few good managers, I will be happy. Good managers are worth a lot of money.”

Technology with creativity

RSA (EMC Information Security division) Israel Director of Research and Innovation CTO Alon Kaufman says that using information for business purposes requires multi-disciplined people, and professional teams need to include, on the one hand, technical people, with backgrounds in statistics, mathematics, or computer science, and, on the other hand, content experts, who understand the business side, and the customers.

“There are very few mathematicians who have a natural business sense, therefore, people who can translate and manage all the technical sides and direct them towards something business oriented that will speak to the customers, and will translate the information in the most practical manner into a final product, are very important. But thinking about the final product has to course through the blood of every one of the workers. So that they have the drive to find the simplest algorithm, and the most practical graphics. When we analyze the data, we need people who know how to ask questions, and know how to present the final product, visually speaking. Such a team could include an architect, a statistician, someone with a degree in computer science, and a physicist. The manager of such a team does not need to be an expert in one of the fields; the manager needs to have the personality traits to allow him to connect everyone, to communicate with the team, and to lead.”

Is it possible to find such people?

“It makes hiring very complicated. Depending on the candidate, you sometimes change the job description, because obviously you will never find yourself exactly. Typically, managers look for people who resemble themselves, but I think this is the biggest mistake - you should search for people who are different.”

At the start-up company Innovid, the employee profile is also atypical for high-tech. “The company’s first employee was a Creative Director, which is a position that does not exist at high-tech companies,” says co-founder and global operations manager Zack Zigdon. “What we are creating is something new, and when you approach a client, you have to show him something to convince him. We need creative people to convince the advertisers.”

Innovid offers advertisers a new way to present their products using videos that present viewers with options to be exposed to more and more information about the product. For instance, a viewer watching a car commercial may be able to book a test drive, view the car’s interior, or receive price quotes, while watching the commercial. The company has a full team of art and design school graduates working on the video advertising experience.

Playtika Israel, which operates in the field of gaming on social networks, and whose primary platform is Facebook, has a hard time finding workers because the company is so specialized. According to head of HR Gabi Karni, she turns to candidates whom, in a typical recruit, she would not be interested in. The company’s content manager is a script writer, and working directly under him is a toy designer. The studio manager previously worked at an ad agency. The marketing manager is an entrepreneur, who previously founded a start-up. One worker was an IDF intelligence officer; his job is to research the competition. “Initially, it was because we had no choice,” says Karni, “But, later, I understood that, surprisingly, the variety and the heterogeneousness bring about our success as an innovative organization that creates products outside of the box. These workers come from a crossroads, seeking a new and challenging path. They come with motivation, hunger, and desire - this is what creates the synergy with the organizations culture and pace. Their learning curve is very steep, and they succeed exceptionally.”

“Also seeking literature majors”

As mentioned, seeking employees who do not fit the classic profile is not only typical in high-tech. McCann Valley (McXann Erickson ad agency Mitzpe Ramon extension) chairwoman Hana Rado, had a hard time finding young workers in the area. Hence, some of the senior staff relocated to the area from Tel Aviv, but there is a clear preference for Negev residents. “We take people with undergraduate degrees, who have no experience, and they undergo 3 months of training. For the time being, the training is in Tel Aviv, but soon it will be in Mitzpe Ramon. We have psychologists, economists, lawyers, communications majors, literature majors, people who understand language. People who like to write like journalists, economists, biologists. People who are interested in the Internet world. Wonderful people with values. It’s like a start-up in the desert."

Published by Globes [online], Israel business news - www.globes-online.com - on December 30, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

 

Globes - Wanted: Arts majors for high-tech

 

 

 

 

 

 

More Articles of Home
Where biotech and high-tech meet
Executives in Israel for the MIXiii conference tell "Globes" about the future of medicine.From Globs2014 is positioned to go down in history as one of the stormiest years for biomed. The Nasdaq Biotechnology Index has risen sharply, by tens of percentage points, since the beginning of the year - a process that opened the door to dozens of IPOs - but has recently lost ground.Pfizer is in talks to acquire AstraZeneca for more than $100 billion, the pharmaceutical and biotech companies continue to launch groundbreaking products, and the field of medical technology is in the throes of a revolution.Senior industry executives from around the world who participated in the MIXiii Israel Innovation Conference (which combined the Israel Advanced Technology Industries annual international biomed conference with a high-tech conference for the first time), spoke to “Globes” about the latest breakthroughs, gave forecasts for the future, and explained what brought them to Israel.According to Pitango Venture Capital General Partner and MIXiii Biomed Co-Chair Ruti Alon, “The forecast in the field of biomed is fundamentally complicated, due to of the interaction between political trends, such as globalization and different modes of distribution that bring Western diseases to new countries, and technological trends, such as genomics.“In light of this, we can expect continued pressure to lower prices, significant changes in marketing systems, broader use of Internet, and the continued rise in prominence of the consumer as a factor in decision making. In Israel, there is a deep understanding of what is required to develop HealthIT products, that will connect the medical community.”DFJ Tel Aviv Venture Partners General Partner and MIXiii Biomed Co-Chair Dr. Benny Zeevi said: “I believe the transitions from hospital care to remote care, from general care to personalized care, from treatment-based care to more preventive care, and higher patient involvement in treatment, will translate into a more pleasant patient experience, and greater commitment to maintaining therapeutic regimes as a result.””More holistic diagnosis and care”Boehringer Ingelheim (BI) seems to be one of the less familiar among the 20 big companies, but only because it is not publicly traded. The company has 50,000 employees, and invests 20% of its revenue in R&D, with an emphasis on internal R&D.The company has, in the past, been in talks to acquire an Israeli company, and has recently established a branch in Israel, headed by Orna Fiat Steinberger. The branch is responsible for running the company’s clinical trials in Israel.The company was established 129 years ago. It was founded by, and is managed still today, by the Boehringer family, and Ingelheim is the German city in which the company was founded. Today, the company has a rich pipeline of products. Chief Medical Officer Prof. Klaus Dugi points in particular to the new cancer drug Volasertib, a small molecule inhibitor that prevents cancer cells from dividing by attacking the PKL1 protein. The company is testing the product for leukemia treatment, and is currently in Phase II clinical trials.According to Dugi, the most significant scientific breakthrough of recent years is the recognition of the role that the mix of live organisms living in and on our bodies has in causing and preventing illness. “Today, using genome sequencing technology, we can know precisely what the genomes of our intestinal bacteria are. These genes, which are not exactly part of our bodies, apparently affect not only diseases of the intestine, but others as well. This knowledge can lead to entirely different medical diagnoses and treatments from those we know today - more holistic diagnosis and care.”Dugi claims that the patent cliff troubles the industry, but not BI, and it is likely to be less problematic for the industry in the future. “In a world where most newly approved products are biological, which are harder to duplicate, it is possible that patent expiry will be regarded differently, and less seriously, in the future.”The real industry crisis is not an R&D crisis, in his opinion is, but rather a budget crisis - governments are unable to maintain the health budgets necessary to create significant continued growth in biotech and pharmaceuticals, and drugs will soon need to prove that they save not only lives and suffering, but also money (as is the case for medical devices today). In order to do this, it will be necessary to improve existing patient monitoring data systems, and to match the best treatment to each patient.Fiat Steinberger says that: “The fact that BI is a private company allows it to invest in R&D without thinking about how the analysts will look at the bottom line next quarter, or even next year, and, therefore, we have many long-term plans.” The company has 90 research projects, and it classifies ten products (in eight categories) as “pre-launch,” which means they are either in advanced Phase II with good results in previous trials, post-Phase III, or they have already been approved.BI also has a venture capital fund that seeks out biomed companies to invest in, including companies in early stages of development that are not yet suitable for traditional venture capital funds. In 2014, the fund invested in a company called Metabomed, which at the same time received investments from the Merck Serono incubator in Yavne, from the Pontifax fund, and from the Technion technology transfer company. The company deals in treatments based on cancer metabolism - treatment through the resources that the cancer consumes.Using stem cells to regenerate tissueOver the past decade, Takeda Pharmaceuticals has gone from being a Japanese pharmaceutical company to being a global giant, competing head to head with the biggest global players. The company’s Israel office is headed by Arie Kramer. Following its acquisitions of US company Millennium Pharmaceuticals, which is developing a cancer treatment, and veteran European pharmaceutical company Nycomed, Takeda has become one of the most significant global powers in the pharmaceutical industry.Despite the acquisitions, Takeda, like all the major pharmaceutical companies, has been forced to contend with the patent cliff: the expiry of patents on leading products, while R&D fails to produce new products at the expected rate.“The patent cliff troubles the pharmaceutical companies and the investors,” said Takeda Head of R&D Tetsuyuki Maruyama, who was tasked with finding a solution to the problem, and has succeeded in doing so.“It seems that the worst is behind us,” he says, “And I believe that the industry has learned from it: to place less emphasis on bestselling drugs, and to vary the product offering.“A decade ago, large pharmaceutical companies avoided anything ‘difficult,’ like cancer, or rare diseases. The smaller companies proved that these are attractive markets, and now the big companies are scurrying to close the gap. We believe that this will happen also for the brain, so as larger companies leave this field, we focus on it.”What are the developments that are likely to have the most significant impacts on the future of medicine?“I believe in a combination of drugs and antibodies, where the antibodies lead the drugs directly to specific targets. Our company has such a product that should reach the market soon, after having waited for years for the right combination.“Using such technology, together with products that use the immune system to treat cancer, I believe that the medical world will actually reach a cure for cancer, and I am not the only one who believes this.“Another exciting technological development is the bacTRAP platform, which we loved so much that we bought the company that developed it. This is technology that allows us to look at changes in gene expression in specific cells in tissue that has many different kinds of cells, where each one expresses genes a little differently.“Using this focus, we can develop far more accurate drugs. This is true for many areas, but most of all the brain, which has a mix of cells. I believe that the field of regenerative medicine, using stem cells to regenerate sick tissue, will lead to breakthroughs.”Maruyama notes that Takeda owns a group called New Frontiers Science Team, which seeks technologies in advanced development stages and whose representatives were at the conference as well.What are the most interesting products in your pipeline?“We just now launched our first cancer drug based on a combination of antibodies and drugs. We are waiting on the launch of a new drug to treat Crohn’s disease and irritable bowel syndrome, which is most effective for patients for whom existing treatments don’t work. We are focusing on the digestive system.”“Israel has an ideal mix”Becton Dickinson (BD) is a medical device supplier that deals in a broad range of products, including hospital lab equipment. The company specializes in cheap medical equipment that is manufactured in large quantities.“I have been with the company for 11 years,” said BD Director of Business Development Al Lauritano, “First, I headed the life science new business incubator in North Carolina, and I have basically held the same job ever since, only the job has grown.”Incubator? That must have been revolutionary, at the time.“We had an incubator from 1998 to 2008, into which we accepted mostly companies from academic institutions, but it wasn’t so successful. The business model was that after our initial investment, more investors were meant to join in, financial institutions, but, in order to attract such investors, the companies were forced to change their business models in directions that interested us less, as strategic investors. So we didn’t get what we wanted out of them.“We never really shut the incubator down, but we became very picky. In the beginning of this year we decided to establish a ‘virtual incubator.’ We won’t host the companies, instead, we will support them wherever they are. We won’t only invest money - we will also send our people. That way, we will be able to get to know the companies well.”In the coming year, BD will announce its first incubator company. “This is one of the reasons I am in Israel” says Lauritano.“We believe that Israel has an ideal mix of entrepreneurs, technology, financing, and operational infrastructure, including the support of the chief scientist. In April, we announced our participation in a collaborative project between the chief scientist and the international corporations. This summer, we will put out a call for opportunities in Israel,” says Lauritano, who worked at Israeli company D-Pharm in the past.Lauritano is particularly interested in combinations of information technologies in daily medical products. “Therefore, it makes sense for us that the conference brings high-tech and biotech together,” he says. He notes that many BD products are in competitive markets, where the product is manufactured by the millions (syringes and catheters, for example).“How can we bring added value to such a product? Adding information technology in or around it is one method. We see that hospitals need to improve their workflows, in order to prevent mistakes in drug administration and to make sure that patients follow through on the treatments that are prescribed to them. So we want as much information as possible to be entered into medical records automatically from our medical devices.”In the future, the company intends to help healthy people as well, “For example, diabetics, who are at the forefront of the population that monitors and manages its health regularly, every single day. Why shouldn’t all the healthy people, or people with chronic diseases, monitor themselves in such a manner in order to maintain optimal health? Our goal is to make a business of this.”What is the most interesting product you have launched in the past two years?“We surprised the industry this year when we announced that were opening a generic drug department. We have always had syringes that added value to drugs, and now, instead of selling them only to companies, we will incorporate generic drugs ourselves.”Published by Globes [online], Israel business news - www.globes-online.com - on May 26, 2014© Copyright of Globes Publisher Itonut (1983) Ltd. 2014 Taken from Globes - Where biotech and high-tech meet
Analysts: Israel to be attractive developed market
 Analysts: Israel to be attractive developed marketDeutsche Bank says although Jewish state will be alongside world's richest economies, its growth characteristics will keep more in line with emerging market Reuters  Published: 05.19.10, 10:28 / Israel Business    Israel will be an attractive investment after its upgrade from an emerging to a developed market this month in the MSCI Index, analysts say. Deutsche Bank said this week that although Israel will be alongside the world's richest economies, its growth characteristics will keep more in line with an emerging market. "(Israel) can offer active developed market investors the opportunity to enjoy emerging style growth and performance without having to invest off-index," the bank said in a report. Index compiler MSCI announced last June it would include Israel in its World Index and its EAFE Index, the third such upgrade in its history. When the May 27 reclassification takes effect, passive investors in emerging markets will have to sell Israel holdings. It may take time for developed market funds to take their place. "The Israeli economy is in relatively good shape. For a developed market investor, Israel would be quite an attractive place," said Andrew Brown, an investment manager at British firm Aberdeen whose emerging market fund has about $700 million in Israeli companies. "These stocks are of relatively good value," he told Reuters. "We will not rush to sell them." Foreign investors surveyed by Thomson Reuters Extel in March said the biggest challenge to the Israeli market would be the shift from comprising about 3% of MSCI's emerging markets index to some 0.4% of its developed market index. Fidelity International's Nick Price, portfolio manager of the Emerging Europe Middle East and Africa Fund, said the switch will not have any effect on his fund because of Israel's size. "I will stay with stocks that I like and I believe that most people will do the same," he said.  Top-heavy market A Citigroup report said $2.8 billion in passive outflows were expected from Israeli stocks with the change – but eventually would be more than offset by inflows of $3.6 billion. Foreign investors already hold nearly 30% of Israeli equities, mostly in top companies like Teva Pharmaceutical Industries, Israel Chemicals, Bezeq Israel Telecom and the largest banks, Leumi and Hapoalim. UBS and Merrill Lynch also view the move as a short-term negative with a more positive long term. The Tel Aviv 25 index hit an all-time high last month of 1,237.85 points, buoyed by strong economic growth. It has eased back to 1,162 with the global decline in stocks. The country recovered relatively quickly from the global crisis, its economy expanding at an annualized 4.8% rate in the fourth quarter and 0.7% for all of 2009. The central bank predicts growth of 3.7% in 2010.  Israel was also invited to join the Organization for Economic Cooperation and Development (OECD) this month. The Bank of Israel said that while there is a chance of an ebb in passive inflows, in previous upgrades there was no evidence of a significant drop in the volume of investment.
Future Technologies in today's labs
Technology and Innovation Making a Better Tomorrow at Research@Intel EventNEWS HIGHLIGHTSToday marks the 11th annual Research@Intel event, showcasing 20 research projects from around the world, each exploring technologies to enrich lives with smarter cities, homes and offices, and with smarter ways to shop, communicate and drive.Intel Labs is developing some of the world's most promising technological advancements, both on its own and in conjunction with leading academic institutions worldwide.Intel Labs helps pave the way for future innovations through technologies that support life enrichment, easier access to big data, and a more connected computing experience.SAN FRANCISCO, June 25, 2013 – Car tail lights saving lives, immersive displays allowing photos to tell their own story, personalized shopping experiences. These are just a few of the innovations presented by Intel Corporation today at its 11th annual Research@Intel event, a showcase of the most innovative new research spawned from Intel's internal efforts and external collaborations. Justin Rattner, Intel's chief technology officer, kicked off today's event by highlighting some of the 20 groundbreaking research projects on exhibition today.Supplementing its own robust and diverse research efforts, Intel Labs two years ago deployed a unique model of direct collaboration with the world's leading academic researchers, creating a global network of seven Intel Science and Technology Centers (ISTCs) and six Intel Collaborative Research Institutes (ICRIs). Each center has built its own vibrant community of researchers to speed advances in embedded, cloud, social and secure computing, among other fields. Today's event showcases a sample of these research advances – and many from Intel's own labs – across these and many other sectors, including visual and context-aware computing as well as significant progress in fields such as big data."The majority of our research is conducted by Intel's own researchers but we are delighted by the quality and quantity of research coming out of the ISTCs and ICRIs," said Rattner. "Importantly, the deeply collaborative structure of these engagements is based on an open IP model benefiting not just Intel and researchers, but the high technology industry and human society at large."Research@Intel Demo ShowcaseDemos at the Research@Intel event are housed in four different zones. These zones include:Enriching Lives: Developing computing experiences that simplify, enhance and enrich people's lives. This research is intended to help people be understood, expressive and free. One demonstration, titled "Be Meaningful," using "Shelf Edge Technology (SET)," can help detect a person's presence in a store and create a more meaningful, personalized shopping experience. If a car needs an air filter, for example, SET could use the vehicle's service records to alert the owner about the need for a specific filter when the owner enters an auto parts store. If a person has peanut allergies, SET could warn of potentially dangerous products. If a person plans to cook salmon for dinner, SET could recommend wines to best compliment the dish.The Data Society: Unlocking the power of data for everyone. In addition to pushing the boundaries of what institutions can do with big data, Intel Labs has put an emphasis on the exploration of meaningful data exchange among individuals. Researchers are looking at ways to adapt the digital infrastructure to allow people to better capture, move and work with digital information easily and effectively. In a demonstration titled, "Vibrant Data Communities," Intel Labs researchers combine public and personal data with context-aware algorithms to identify and present the most useful information to individuals. For example, air quality sensors in a neighborhood could help steer a person clear of pollen hotspots in during allergy season.Intelligent Everything: Innovations that transform inanimate objects by adding sensing capabilities, helping enable sustainable and smart living experiences. In one demonstration, researchers are working on easy-to-use tools to automate contextual cues with already-existing sensors so that a home behaves usefully in response to events and a family's unique needs. The demonstration shows how to easily link a Web camera and a music system to act as a home security system and to link a Web camera that receives contextual cues from a baby in a crib and an alarm by the parents' bed to act as a baby monitor.Tech Essentials: Technology building blocks – including circuits, architecture and software – that provide a foundation for all of the areas above. For example, the "Protecting Sensor Data" demonstration uses Intel hardware and software to prevent malicious parties for accessing personal information recorded by cameras, microphones and GPS locators embedded in mobile devices.To get the latest Intel Innovation news, visit www.intel.com/newsroom/research, and join the conversation on Facebook and Twitter.
up


Last Articles


Made in Israel - an online exhibition and catalog of Israeli Products & Services made for export
2015 Jun 14
Wanted: Arts majors for high-tech From Globs Technology companies are looking for creativ...
Published by Dafna Barmeli-Golan
Made in Israel - an online exhibition and catalog of Israeli Products & Services made for export
2014 Aug 31
World's biggest fund discovers Tel Aviv From Globs Last year, Rami Levy joined BTI, the g...
Published by Amiram Barkat
Made in Israel - an online exhibition and catalog of Israeli Products & Services made for export
2014 Jul 07
Everyone wins when a big company acquires a start-up. From Globs Exactly three years ago,...
Published by Roy Goldenberg
Made in Israel - an online exhibition and catalog of Israeli Products & Services made for export
2014 Jul 07
Executives in Israel for the MIXiii conference tell "Globes" about the future of medici...
Published by Gali Weinreb